PL
RAPT

Portland Ltd’s RAPT Therapeutics RAPT Stock Holding History

Portland Ltd’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$542K Buy
+2,104
New +$467K 1.2% 4

Other funds holding RAPT

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Portland Ltd's RAPT Position: Q3 2020 in Review

Portland Ltd opened a new position in RAPT Therapeutics (RAPT) in Q3 2020: 2,104 shares worth $542K. The stake represents 1.2% of the portfolio and ranks #4 among its holdings.

67 funds tracked by Wall St. Rank hold RAPT as of Q3 2020.

  • Portland Ltd held 2,104 shares of RAPT Therapeutics worth $542K as of Q3 2020.
  • RAPT Therapeutics was a new Portland Ltd position in Q3 2020.
  • RAPT Therapeutics made up 1.2% of Portland Ltd's portfolio in Q3 2020, its #4 holding.
  • 67 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2020.

Based on Portland Ltd's 13F filing for Q3 2020, filed 27 Oct 2020.